Yoon Pin Lim
Overview
Explore the profile of Yoon Pin Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
799
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lim Y, Lin H, Seah S, Lim Y
Cells
. 2021 Nov;
10(11).
PMID: 34831354
Cancer is a global health problem. The delineation of molecular mechanisms pertinent to cancer initiation and development has spurred cancer therapy in the form of precision medicine. The Hippo signalling...
2.
Lim Y, Lin H, Chu T, Lim Y
Mol Oncol
. 2021 Jul;
16(2):422-446.
PMID: 34197030
WW-domain-binding protein 2 (WBP2) is an oncogene that drives breast carcinogenesis through regulating Wnt, estrogen receptor (ER), and Hippo signaling. Recent studies have identified neoteric modes of action of WBP2...
3.
Tabatabaeian H, Lim S, Chu T, Seah S, Lim Y
Life Sci Alliance
. 2021 Jun;
4(7).
PMID: 34117091
WBP2 is an emerging oncoprotein with diverse functions in breast tumorigenesis via regulating Wnt, epidermal growth factor receptor, estrogen receptor, and Hippo. Recently, evidence shows that WBP2 is tightly regulated...
4.
Hum M, Tan H, Yang Y, Srivastava S, Teh M, Lim Y
FASEB J
. 2021 Jan;
35(2):e21290.
PMID: 33475198
Dysregulation of signaling pathways is responsible for many human diseases. The lack of understanding of the molecular etiology of gastric cancer (GC) poses a substantial challenge to the development of...
5.
Lim S, Tabatabaeian H, Lu S, Kang S, Sundaram G, Sampath P, et al.
Cell Death Dis
. 2020 Aug;
11(8):669.
PMID: 32820148
WBP2 transcription coactivator is an emerging oncoprotein and a key node of convergence between EGF and Wnt signaling pathways. Understanding how WBP2 is regulated has important implications for cancer therapy....
6.
Tabatabaeian H, Rao A, Ramos A, Chu T, Sudol M, Lim Y
Oncogene
. 2020 May;
39(24):4621-4635.
PMID: 32393834
WW domain-binding protein 2 (WBP2) is an emerging oncoprotein. Over the past decade, WBP2 surfaced as a key node connecting key signaling pathways associated with ER/PR, EGFR, PIK, Hippo, and...
7.
Kang S, Guan J, Tan H, Chu T, Thike A, Bernado C, et al.
Clin Cancer Res
. 2018 Dec;
25(8):2588-2600.
PMID: 30593516
Purpose: Trastuzumab-based chemotherapy has shown remarkable clinical benefits for patients with HER2-positive breast cancer. However, treatment regimens involving trastuzumab had little or no effect for a subset of patients. Preliminary...
8.
Li Z, Lim S, Liang X, Lim Y
J Biol Chem
. 2018 Nov;
293(52):20014-20028.
PMID: 30442712
The transcriptional coactivator WW domain-binding protein 2 (WBP2) is an emerging oncogene and serves as a node between the signaling protein Wnt and other signaling molecules and pathways, including epidermal...
9.
Ramos A, Miow Q, Liang X, Lin Q, Putti T, Lim Y
FASEB J
. 2018 Sep;
:fj201801167RR.
PMID: 30183375
WW domain binding protein 2 (WBP2), a transcriptional coactivator, plays a vital role in breast tumorigenesis. It positively regulates estrogen receptor, Hippo, and Wnt pathways, which subsequently enhance the transcription...
10.
Jiang H, Hu H, Lin F, Lim Y, Hua Y, Tong X, et al.
Cancer Invest
. 2016 Dec;
34(10):477-488.
PMID: 27918216
S100P is known to affect tumor development and metastasis of various cancers, but its role in endometrial cancer is unclear. We reported that S100P expression was dramatically elevated in both...